Skip to main content
. Author manuscript; available in PMC: 2023 Feb 24.
Published in final edited form as: J Med Chem. 2022 Feb 4;65(4):3644–3666. doi: 10.1021/acs.jmedchem.1c02165

Figure 1.

Figure 1.

Design of putative AKT degraders. (A) Co-crystal structure of AKT1 (in gray) in complex with AZD5363 (in green, blue, and red) (PDB: 4GV1). The hydroxyl group of AZD5363 (marked by the orange cycle) is solvent-exposed. (B) Schematic design of AKT putative degraders based upon the AKT inhibitor AZD5363.